Seven months after clinical trials for a promising Alzheimer’s drug were halted and the treatment was declared a failure, a new analysis suggests it was actually effective, and the company that makes it plans to move forward in securing federal approval.
The settlement means a high-profile trial in Ohio will not move forward, but it does not resolve more than 2,600 other lawsuits across the country seeking to hold the drug industry accountable for a crisis that has been linked to more than 400,000 U.S. deaths since 2000.
Outlines of a settlement call for $22 billion in cash over time plus up to $15 billion worth of overdose antidotes and treatment drugs, with distribution of those drugs valued at another $14 billion.
The drug, called pegilodecakin, had been seen as a promising treatment for one of the deadliest types of cancer, and was the lead product in Lilly’s $1.6 billion acquisition of Armo BioSciences last year.
Vice President Mike Pence stumped for President Trump’s proposed deal with Mexico and Canada during a rally Thursday at McAllister Machinery on the city’s southeast side.
The owner of Pace Air Freight, which specializes in truck transport of pharmaceutical products, is in the process of assembling land it doesn’t already own, including parcels owned by Indianapolis International Airport.
Indiana Attorney General Curtis Hill is among the 29 attorneys general across the country backing a proposed settlement with OxyContin maker Purdue Pharma, calling the agreement a “significant breakthrough in our important fight against the opioid crisis.”
Paul Elmer, 68, of Fishers, was sentenced Wednesday in U.S. District Court in Indianapolis, six months after a jury found him guilty of nine counts of adulterating compounded drugs and one count of conspiracy.
Purdue Pharma may have just set the starting point for determining what it will cost dozens of pharmaceutical companies to resolve legal liability over their role in creating the U.S. opioid epidemic.
By Thursday, half of the nation’s state attorneys general said they would reject a tentative deal crafted by the other half, and many criticized the terms as grossly insufficient.
A tentative settlement announced Wednesday over the role Purdue Pharma played in the nation’s opioid addiction crisis falls short of the far-reaching national settlement the OxyContin maker had been seeking for months, with litigation sure to continue.
Last year, Taltz rang up sales of $937.5 million, and doctors are increasingly prescribing it. For the first six months of this year, Taltz recorded $606.3 million in sales, putting it on pace to break the $1 billion threshold, perhaps in the third quarter.
The formulas would take into account several factors, including opioid distribution in a given jurisdiction, the number of people who misuse opioids and the number of overdose deaths.
While the price of almost any good or service can be found online, most Americans don’t know what they’ll owe for a prescription medication until they get it.
Drugmaker Purdue Pharma is negotiating a multibillion-dollar settlement with lawyers for local and state governments that would resolve about 2,000 lawsuits against the company.
Indiana accounted for 4% of the nation’s opioid-related deaths, but received just 1.9% of the nation’s $11 billion opioid-related funding awarded to states over the past two years, according to the new study.
After years of frequent list price hikes, many drugmakers are showing some restraint, according to the analysis of drug prices.
President Donald Trump’s plan to import cheap Canadian drugs overlooks a crucial fact: Canada’s pharmaceutical supply chain is beholden to the drugmakers.
The Trump administration said Wednesday it will create a pathway allowing Americans to legally and safely import lower-cost prescription drugs from Canada for the first time, reversing years of opposition from federal health authorities.
The new publicly traded company will have sales of about $19 billion to $20 billion in 2020, the drugmakers said in a statement.
